Summary

The global Nucleic Acid Drugs market size is projected to reach US$ 15538.36 million by 2029, from US$ 12486.73 million in 2023, at a CAGR of 3.71% during 2023-2029
The US & Canada market for Nucleic Acid Drugs is estimated to increase from $ 4357.7 million in 2023 to reach $ 7917.6 million by 2029, at a CAGR of 10.46% during the forecast period of 2023 through 2029.
The Europe market for Nucleic Acid Drugs is estimated to increase from $ 5570.25 million in 2023 to reach $ 4295.09million by 2029, at a CAGR of -4.24% during the forecast period of 2023 through 2029.
The global key companies of Nucleic Acid Drugs include Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2022, the global top five players had a share approximately 97.87% in terms of revenue.

Report Includes
This report presents an overview of global market for Nucleic Acid Drugs market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Nucleic Acid Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Nucleic Acid Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nucleic Acid Drugsrevenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Nucleic Acid Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Nucleic Acid Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, BioNTech, Nippon Shinyaku, Moderna Therapeutics, CureVac, and Biogen, etc.

By Company
On Market Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
On Pipeline Company
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna

Segment by Type
Antisense Oligonucleotides (ASOs) Drugs
Small Interfering RNA (siRNA) Drugs
mRNA Drugs
Others

Segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other

By Region
North America
United States
Canada
China

Asia-Pacific
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia

Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe

Latin America, Middle East & Africa
Mexico
Brazil
Rest of Latin America

Middle East
Africa

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Nucleic Acid Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid Drugs companies's competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nucleic Acid Drugsrevenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

ページTOPに戻る

Table of Contents

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Nucleic Acid Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1
1.2.2 Antisense Oligonucleotides (ASOs) Drugs 3
1.2.3 Small Interfering RNA (siRNA) Drugs 5
1.2.4 mRNA Drugs 6
1.3 Market by Application 7
1.3.1 Global Nucleic Acid Drugs Market Share by Application: 2018 VS 2022 VS 2029 8
1.3.2 Neuromuscular Diseases 9
1.3.3 hATTR 10
1.3.4 COVID-19 11
1.4 Assumptions and Limitations 12
1.5 Study Objectives 13
1.6 Years Considered 14
2 Global Growth Trends 15
2.1 Global Nucleic Acid Drugs Market Perspective (2018-2029) 15
2.2 Global Nucleic Acid Drugs Growth Trends by Region 16
2.2.1 Global Nucleic Acid Drugs Market Size by Region: 2018 VS 2022 VS 2029 17
2.2.2 Nucleic Acid Drugs Historic Market Size by Region (2018-2023) 18
2.2.3 Nucleic Acid Drugs Forecasted Market Size by Region (2024-2029) 19
2.3 Nucleic Acid Drugs Market Dynamics 20
2.3.1 Nucleic Acid Drugs Industry Trends 20
2.3.2 Nucleic Acid Drugs Market Drivers 21
2.3.3 Nucleic Acid Drugs Market Challenges 22
2.3.4 Nucleic Acid Drugs Market Restraints 22
3 Competition Landscape by Key Players 24
3.1 Global Revenue Nucleic Acid Drugs by Players 24
3.1.1 Global Nucleic Acid Drugs Revenue by Players (2018-2023) 24
3.1.2 Global Nucleic Acid Drugs Revenue Market Share by Players (2018-2023) 25
3.2 Global Nucleic Acid Drugs Market by Company Type (Tier 1, Tier 2, and Tier 3) 26
3.3 Global Key Players of Nucleic Acid Drugs, Ranking by Revenue, 2021 VS 2022 VS 2023 27
3.4 Global Nucleic Acid Drugs Market Concentration Ratio 28
3.4.1 Global Nucleic Acid Drugs Market Concentration Ratio (CR5 and HHI) 28
3.4.2 Global Top 5 Companies by Nucleic Acid Drugs Revenue in 2022 29
3.5 Global Key Players of Nucleic Acid Drugs Head office and Area Served 29
3.6 Global Key Players of Nucleic Acid Drugs, Product and Application 30
3.7 Global Key Players Established Date 32
3.8 Mergers & Acquisitions, Expansion Plans 32
4 Nucleic Acid Drugs Breakdown Data by Type 34
4.1 Global Nucleic Acid Drugs Historic Market Size by Type (2018-2023) 34
4.2 Global Nucleic Acid Drugs Forecasted Market Size by Type (2024-2029) 35
5 Nucleic Acid Drugs Breakdown Data by Application 36
5.1 Global Nucleic Acid Drugs Historic Market Size by Application (2018-2023) 36
5.2 Global Nucleic Acid Drugs Forecasted Market Size by Application (2024-2029) 37
6 North America 38
6.1 North America Nucleic Acid Drugs Market Size (2018-2029) 38
6.2 North America Nucleic Acid Drugs Market Size by Type 38
6.2.1 North America Nucleic Acid Drugs Market Size by Type (2018-2023) 38
6.2.2 North America Nucleic Acid Drugs Market Size by Type (2024-2029) 39
6.2.3 North America Nucleic Acid Drugs Market Share by Type (2018-2029) 39
6.3 North America Nucleic Acid Drugs Market Size by Application 40
6.3.1 North America Nucleic Acid Drugs Market Size by Application (2018-2023) 40
6.3.2 North America Nucleic Acid Drugs Market Size by Application (2024-2029) 40
6.3.3 North America Nucleic Acid Drugs Market Share by Application (2018-2029) 41
6.4 North America Nucleic Acid Drugs Market Size by Country 41
6.4.1 North America Nucleic Acid Drugs Market Size by Country: 2018 VS 2022 VS 2029 41
6.4.2 North America Nucleic Acid Drugs Market Size by Country (2018-2023) 42
6.4.3 North America Nucleic Acid Drugs Market Share by Country (2024-2029) 42
6.4.4 United States 43
6.4.5 Canada 43
7 Europe 44
7.1 Europe Nucleic Acid Drugs Market Size (2018-2029) 44
7.2 Europe Nucleic Acid Drugs Market Size by Type 44
7.2.1 Europe Nucleic Acid Drugs Market Size by Type (2018-2023) 44
7.2.2 Europe Nucleic Acid Drugs Market Size by Type (2024-2029) 45
7.2.3 Europe Nucleic Acid Drugs Market Share by Type (2018-2029) 45
7.3 Europe Nucleic Acid Drugs Market Size by Application 46
7.3.1 Europe Nucleic Acid Drugs Market Size by Application (2018-2023) 46
7.3.2 Europe Nucleic Acid Drugs Market Size by Application (2024-2029) 46
7.3.3 Europe Nucleic Acid Drugs Market Share by Application (2018-2029) 47
7.4 Europe Nucleic Acid Drugs Market Size by Country 47
7.4.1 Europe Nucleic Acid Drugs Market Size by Country: 2018 VS 2022 VS 2029 47
7.4.2 Europe Nucleic Acid Drugs Market Size by Country (2018-2023) 48
7.4.3 Europe Nucleic Acid Drugs Market Size by Country (2024-2029) 48
7.4.4 Germany 49
7.4.5 France 50
7.4.6 U.K. 50
7.4.7 Italy 51
7.4.8 Russia 51
8 China 52
8.1 China Nucleic Acid Drugs Market Size (2018-2029) 52
8.2 China Nucleic Acid Drugs Market Size by Type 52
8.2.1 China Nucleic Acid Drugs Market Size by Type (2018-2023) 52
8.2.2 China Nucleic Acid Drugs Market Size by Type (2024-2029) 53
8.2.3 China Nucleic Acid Drugs Market Share by Type (2018-2029) 53
8.3 China Nucleic Acid Drugs Market Size by Application 54
8.3.1 China Nucleic Acid Drugs Market Size by Application (2018-2023) 54
8.3.2 China Nucleic Acid Drugs Market Size by Application (2024-2029) 54
8.3.3 China Nucleic Acid Drugs Market Share by Application (2018-2029) 55
9 Asia (excluding China) 56
9.1 Asia Nucleic Acid Drugs Market Size (2018-2029) 56
9.2 Asia Nucleic Acid Drugs Market Size by Type 56
9.2.1 Asia Nucleic Acid Drugs Market Size by Type (2018-2023) 56
9.2.2 Asia Nucleic Acid Drugs Market Size by Type (2024-2029) 57
9.2.3 Asia Nucleic Acid Drugs Market Share by Type (2018-2029) 57
9.3 Asia Nucleic Acid Drugs Market Size by Application 58
9.3.1 Asia Nucleic Acid Drugs Market Size by Application (2018-2023) 58
9.3.2 Asia Nucleic Acid Drugs Market Size by Application (2024-2029) 58
9.3.3 Asia Nucleic Acid Drugs Market Share by Application (2018-2029) 59
9.4 Asia Nucleic Acid Drugs Market Size by Region 59
9.4.1 Asia Nucleic Acid Drugs Market Size by Region: 2018 VS 2022 VS 2029 59
9.4.2 Asia Nucleic Acid Drugs Market Size by Region (2018-2023) 60
9.4.3 Asia Nucleic Acid Drugs Market Size by Region (2024-2029) 60
9.4.4 Japan 61
9.4.5 South Korea 62
9.4.6 Southeast Asia 62
9.4.7 India 63
9.4.8 Australia 63
10 Middle East, Africa, and Latin America 64
10.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size (2018-2029) 64
10.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Type 64
10.2.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Type (2018-2023) 64
10.2.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Type (2024-2029) 65
10.2.3 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Share by Type (2018-2029) 65
10.3 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Application 66
10.3.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Application (2018-2023) 66
10.3.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Application (2024-2029) 66
10.3.3 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Share by Application (2018-2029) 67
10.4 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country 67
10.4.1 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country: 2018 VS 2022 VS 2029 67
10.4.2 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country (2018-2023) 68
10.4.3 Middle East, Africa, and Latin America Nucleic Acid Drugs Market Size by Country (2024-2029) 68
10.4.4 Brazil 69
10.4.5 Mexico 70
10.4.6 Middle East 70
10.4.7 Africa 71
11 Key Players Profiles 72
11.1 Sarepta Therapeutics 72
11.1.1 Sarepta Therapeutics Company Details 72
11.1.2 Sarepta Therapeutics Business Overview 72
11.1.3 Sarepta Therapeutics Nucleic Acid Drugs Introduction 73
11.1.4 Sarepta Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023) 74
11.1.5 Sarepta Therapeutics Recent Development 74
11.2 Ionis Pharmaceuticals 75
11.2.1 Ionis Pharmaceuticals Company Details 75
11.2.2 Ionis Pharmaceuticals Business Overview 75
11.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Introduction 76
11.2.4 Ionis Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2018-2023) 78
11.2.5 Ionis Pharmaceuticals Recent Development 78
11.3 Alnylam 78
11.3.1 Alnylam Company Details 78
11.3.2 Alnylam Business Overview 79
11.3.3 Alnylam Nucleic Acid Drugs Introduction 80
11.3.4 Alnylam Revenue in Nucleic Acid Drugs Business (2018-2023) 81
11.3.5 Alnylam Recent Development 81
11.4 Biogen 81
11.4.1 Biogen Company Details 81
11.4.2 Biogen Business Overview 82
11.4.3 Biogen Nucleic Acid Drugs Introduction 82
11.4.4 Biogen Revenue in Nucleic Acid Drugs Business (2018-2023) 84
11.4.5 Biogen Recent Development 84
11.5 Nippon Shinyaku 85
11.5.1 Nippon Shinyaku Company Details 85
11.5.2 Nippon Shinyaku Business Overview 85
11.5.3 Nippon Shinyaku Nucleic Acid Drugs Introduction 86
11.5.4 Nippon Shinyaku Revenue in Nucleic Acid Drugs Business (2018-2023) 87
11.5.5 Nippon Shinyaku Recent Development 87
11.6 Sobi 87
11.6.1 Sobi Company Details 87
11.6.2 Sobi Business Overview 88
11.6.3 Sobi Nucleic Acid Drugs Introduction 88
11.6.4 Sobi Revenue in Nucleic Acid Drugs Business (2018-2023) 89
11.6.5 Sobi Recent Development 89
11.7 Novartis 90
11.7.1 Novartis Company Details 90
11.7.2 Novartis Business Overview 90
11.7.3 Novartis Nucleic Acid Drugs Introduction 91
11.7.4 Novartis Revenue in Nucleic Acid Drugs Business (2018-2023) 91
11.7.5 Novartis Recent Development 91
11.8 BioNTech 92
11.8.1 BioNTech Company Details 92
11.8.2 BioNTech Business Overview 92
11.8.3 BioNTech Nucleic Acid Drugs Introduction 93
11.8.4 BioNTech Revenue in Nucleic Acid Drugs Business (2018-2023) 94
11.8.5 BioNTech Recent Development 94
11.9 Pfizer 95
11.9.1 Pfizer Company Details 95
11.9.2 Pfizer Business Overview 96
11.9.3 Pfizer Nucleic Acid Drugs Introduction 96
11.9.4 Pfizer Revenue in Nucleic Acid Drugs Business (2018-2023) 97
11.9.5 Pfizer Recent Development 97
11.10 Moderna Therapeutics 98
11.10.1 Moderna Therapeutics Company Details 98
11.10.2 Moderna Therapeutics Business Overview 99
11.10.3 Moderna Therapeutics Nucleic Acid Drugs Introduction 99
11.10.4 Moderna Therapeutics Revenue in Nucleic Acid Drugs Business (2018-2023) 100
11.10.5 Moderna Therapeutics Recent Development 101
11.11 Jazz Pharmaceuticals 101
11.11.1 Jazz Pharmaceuticals Company Details 101
11.11.2 Jazz Pharmaceuticals Business Overview 101
11.11.3 Jazz Pharmaceuticals Nucleic Acid Drugs Introduction 102
11.11.4 Jazz Pharmaceuticals Revenue in Nucleic Acid Drugs Business (2018-2023) 103
11.11.5 Jazz Pharmaceuticals Recent Development 104
11.12 CureVac 104
11.12.1 CureVac Company Details 104
11.12.2 CureVac Business Overview 105
11.12.3 CureVac Nucleic Acid Drugs Introduction 105
11.12.4 CureVac Recent Development 106
11.13 Regulus Therapeutics 107
11.13.1 Regulus Therapeutics Company Details 107
11.13.2 Regulus Therapeutics Business Overview 107
11.13.3 Regulus Therapeutics Nucleic Acid Drugs Introduction 108
11.13.4 Regulus Therapeutics Recent Development 108
11.14 ProQR 109
11.14.1 ProQR Company Details 109
11.14.2 ProQR Business Overview 109
11.14.3 ProQR Nucleic Acid Drugs Introduction 110
11.14.4 ProQR Recent Development 110
11.15 Secarna 111
11.15.1 Secarna Company Details 111
11.15.2 Secarna Business Overview 111
11.15.3 Secarna Nucleic Acid Drugs Introduction 112
11.15.4 Secarna Recent Development 112
11.16 MiNA Therapeutics 113
11.16.1 MiNA Therapeutics Company Details 113
11.16.2 MiNA Therapeutics Business Overview 114
11.16.3 MiNA Therapeutics Nucleic Acid Drugs Introduction 114
11.16.4 MiNA Therapeutics Recent Development 115
11.17 Sylentis 115
11.17.1 Sylentis Company Details 115
11.17.2 Sylentis Business Overview 116
11.17.3 Sylentis Nucleic Acid Drugs Introduction 116
11.17.4 Sylentis Recent Development 117
11.18 Arrowhead 117
11.18.1 Arrowhead Company Details 117
11.18.2 Arrowhead Business Overview 118
11.18.3 Arrowhead Nucleic Acid Drugs Introduction 118
11.18.4 Arrowhead Recent Development 119
11.19 Silence Therapeutics 119
11.19.1 Silence Therapeutics Company Details 119
11.19.2 Silence Therapeutics Business Overview 119
11.19.3 Silence Therapeutics Nucleic Acid Drugs Introduction 120
11.19.4 Silence Therapeutics Recent Development 121
11.20 Dicerna 121
11.20.1 Dicerna Company Details 121
11.20.2 Dicerna Business Overview 121
11.20.3 Dicerna Nucleic Acid Drugs Introduction 122
11.20.4 Dicerna Recent Development 123
12 Analyst's Viewpoints/Conclusions 124
13 Appendix 126
13.1 Research Methodology 126
13.1.1 Methodology/Research Approach 126
13.1.2 Data Source 129
13.2 Author Details 132
13.3 Disclaimer 134